Delta3, fthma-070, tango85, tango77, spoil, neokine, tango129, and integrin alpha subunit protein and nucleic acid molecules and uses thereof
Abstract
The invention provides novel Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 polypeptides, proteins, and nucleic acid molecules. In addition to isolated, full-length Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 proteins, the invention further provides isolated Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 fusion proteins, antigenic peptides and anti-Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 antibodies. The invention also provides Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 or A259 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
Claims
exact text as granted — not AI-modified1 - 12 . (canceled)
13 . An isolated nucleic acid molecule selected from the group consisting of: a) a nucleic acid molecule comprising a nucleotide sequence which is at least 80% identical to the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO:3; b) a nucleic acid molecule comprising a fragment of at least 500 nucleotides of the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3; c) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2; d) a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the fragment comprises at least 100 contiguous amino acids of SEQ ID NO:2; and e) a nucleic acid molecule which encodes a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID NO:1, 3, or a complement thereof, under stringent conditions.
14 . The isolated nucleic acid molecule of claim 13 , which is selected from the group consisting of: a) a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3; and b) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2.
15 . The nucleic acid molecule of claim 13 further comprising vector nucleic acid sequences.
16 . A host cell which contains the nucleic acid molecule of claim 13 .
17 . An isolated polypeptide selected from the group consisting of: a) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 80% identical to a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, or a complement thereof; b) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:1 or SEQ ID NO:3; and c) a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the fragment comprises at least 100 contiguous amino acids of SEQ ID NO:2.
18 . The isolated polypeptide of claim 17 , comprising the amino acid sequence of SEQ ID NO:2.
19 . The isolated polypeptide of claim 17 further comprising heterologous amino acid sequences.
20 . A method for detecting the presence of a polypeptide of claim 17 in a sample, comprising: contacting the sample with a compound which selectively binds to a polypeptide of claim 17 ; and determining whether the compound binds to the polypeptide in the sample.
21 . The method of claim 20 , wherein the compound which binds to the polypeptide is an antibody.
22 . A method for detecting the presence of a nucleic acid molecule of claim 13 in a sample, comprising the steps of: contacting the sample with a nucleic acid probe or primer which selectively hybridizes to the nucleic acid molecule; and determining whether the nucleic acid probe or primer binds to a nucleic acid molecule in the sample.
23 . The method of claim 22 , wherein the sample comprises mRNA molecules and is contacted with a nucleic acid probe.
24 . A method for identifying a compound which binds to a polypeptide of claim 17 comprising the steps of: contacting a polypeptide, or a cell expressing a polypeptide of claim 17 with a test compound; and determining whether the polypeptide binds to the test compound.
25 . A method for identifying a compound which modulates the activity of a polypeptide of claim 17 , comprising: contacting a polypeptide of claim 17 with a test compound; and determining the effect of the test compound on the activity of the polypeptide to thereby identify a compound which modulates the activity of the polypeptide.
26 . An isolated antibody, or portion thereof, that specifically binds to a polypeptide selected from the group consisting of: a) the polypeptide comprising the amino acid sequence of SEQ ID NO:2; b) the polypeptide encoded by the nucleic acid molecule of SEQ ID NO: 1 or 3; and c) the polypeptide encoded by the nucleotide sequence contained in the plasmid deposited with the ATCC as Accession number 98348.
27 . The antibody, or portion thereof, of claim 26 , wherein said antibody is selected from the group consisting of: i) a monoclonal antibody; ii) a polyclonal antibody; iii) a bispecific antibody; and iii) a chimeric antibody.
28 . The antibody, or portion thereof, of claim 26 , wherein said portion is a F(ab) fragment or a F(ab′) 2 fragment.
29 . The antibody, or portion thereof, of claim 26 , wherein said antibody binds to amino acid residues 18-529 of SEQ ID NO:2.
30 . The antibody, or portion thereof, of claim 26 , wherein said antibody is detectably labeled.
31 . The antibody, or portion thereof, of claim 30 , wherein the detectable label is selected from the group consisting of: a) an enzyme; b) a fluorescent material; c) a luminescent material; d) a bioluminescent material; and e) a radioactive material.Join the waitlist — get patent alerts
Track US2013316343A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.